Alnylam Pharmaceuticals
ALNY
#632
Rank
A$54.81 B
Marketcap
A$410.79
Share price
-4.32%
Change (1 day)
2.08%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): A$2.66

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$2.50. In 2023 the company made an earnings per share (EPS) of A-$4.90 an increase over its 2022 EPS that were of A-$12.89.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$2.66
2023A-$4.90-62%
2022A-$12.8929.03%
2021A-$9.99-3.36%
2020A-$10.34-8.48%
2019A-$11.297.67%
2018A-$10.4939.74%
2017A-$7.5112.94%
2016A-$6.6538.84%
2015A-$4.79-32.88%
2014A-$7.13259.44%
2013A-$1.98-31.25%
2012A-$2.89

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$9.99 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$2.86 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$59.82 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$3.80-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.01-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.33-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$1.72-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$0.49-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA